Genesis Molecular AI, formerly Genesis Therapeutics, is an AI drug discovery company that applies generative and predictive deep learning to design novel small-molecule medicines. Its GEMS (Genesis Exploration of Molecular Space) platform combines proprietary AI models with physics-based simulation to navigate vast chemical space and optimize drug candidates for potency, selectivity, and developability. The company pursues both internal therapeutic programs and partnerships with large pharmaceutical companies, positioning AI as a way to tackle traditionally 'undruggable' targets and accelerate the discovery timeline. Genesis raised a $200M Series B led by Andreessen Horowitz (Bio + Health) with BlackRock, Fidelity, NVIDIA's NVentures, and others, bringing total funding to over $280M to scale its GEMS platform and advance its pipeline.